source
- Study finds many telehealth sites prescribe GLP-1 weight-loss drugs with minimal clinical oversightA secret-shopper investigation examined 49 direct-to-consumer telehealth platforms that offer GLP-1 medicines such as semaglutide and tirzepatide for weight loss. Researchers posing as patients fo…
- Gene-editing biotech Scribe Therapeutics files for Nasdaq IPOScribe Therapeutics, a California-based biotechnology startup developing genetic medicines for cardiometabolic disorders, announced plans to go public on the Nasdaq under the ticker SCTX. The comp…